Bluejay Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://bluejaytx.com
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Phase 2
Recruiting
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Brelovitug 300 mgDrug: Brelovitug 900 mgDrug: Delayed Treatment with Brelovitug 300mg
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Bluejay Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06907290
- Locations
- 🇺🇸
Garden Grove, Garden Grove, California, United States
🇺🇸Huntington Beach, Huntington Beach, California, United States
🇺🇸Walnut Creek, Walnut Creek, California, United States
© Copyright 2025. All Rights Reserved by MedPath